Simcere Pharmaceutical Group (2096) Fundamentals 2026 — P/E 21.7x, Revenue Analysis | SniperIQ
Simcere Pharmaceutical Group (2096) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Simcere Pharmaceutical Group (2096) has a market capitalization of approximately HK
Simcere Pharmaceutical Group's trailing twelve-month P/E ratio is 21.7x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Simcere Pharmaceutical Group runs a net profit margin of 17.4%, a gross margin of 81.6%, and an operating margin of 20.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Simcere Pharmaceutical Group reported revenue of ¥7.7B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 0.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Simcere Pharmaceutical Group offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Simcere Pharmaceutical Group carries a debt-to-equity ratio of 0.13x and a current ratio of 2.21x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Simcere Pharmaceutical Group (2096) the key facts are: market cap HK
Get Simcere Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.